Morgan Stanley initiated coverage of Novo Nordisk (NVO) with an Equal Weight rating and DKK 700 price target The firm says near-term U.S.

The pen needles market valued at US$ 1.69 Billion in 2023, is forecasted to grow at a robust CAGR of 9.2%, reaching US$ 1.81 Billion in 2024 ...

Novo Nordisk and Eli Lilly have used submissions to the federal government’s budget process to argue reducing obesity will be ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

Danish weight-loss drug maker Novo Nordisk (NVO) is jumping 5% after the company reported higher-than-expected net income for the fourth quarter. Additionally, the company’s CEO now believes that it ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday ...

Novo Nordisk expects sales growth to slow this year as capacity constraints, intensifying competition and pricing pressure drag on sales of its blockbuster weight-loss and diabetes drugs. The Danish ...

Pen Needles Market Insight BURLINGAME, CA, UNITED STATES, February 5, 2025 /EINPresswire / -- The Pen Needles Market Report is the result of e ...